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To investigate the possibility that cigarette smoking and other drug use are af- 
fected by menstrual phase in smokers with Late Luteal Phase Dysphoric Disorder 
(LLPDD), we examined daily diaries rating menstrual symptomatology, smoking, 
alcohol and nonprescription drug use, and caffeine intake in nine female smokers 
meeting criteria for LLPDD. Menstrual symptomatology peaked during the pre- 
menstrual phase. Smoking, alcohol, and nonprescription drug intake were in- 
creased during menses; caffeine intake was unaffected by phase. No systematic 
intrasubject correlation between symptomatology and smoking was detected. It was 
concluded that in women with LLPDD, smoking and alcohol and nonprescription 
drug intake appear to vary as a function of  menstrual phase. The lack of intrasub- 
ject correlations between symptomatology and intake, and the failure of peak intake 
to coincide with peak symptomatology, however, indicate that these effects cannot 
be explained simply as "self-medication" of  acute episodes of dysphoric mood. 
Data were collected by the first author as part of her doctoral dissertation at the University of  
Connecticut; the work was supported by a grant from the University of Connecticut Foundation to 
the fourth author and a grant from the University of  Connecticut Health Center to the second 
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National Cancer Institute. The authors wish to thank Nancy Reame for her helpful comments on an 
earlier draft of this manuscript. 
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Although a number of investigators have attempted to determine whether 
menstrual cycle phase affects intake of a number of drugs, including caffeine 
(Schechter, Bachmann, Vaitukaitis, Phillips, & Saperstein, 1989), alcohol (Mello, 
1986; Schechter et al., 1989), marijuana (Griffin, Mendelson, Mello, & Lex, 
1986), and nicotine (Mello, Mendelson, & Palmieri, 1987; Pomerleau, Cole, 
Lumley, Marks, & Pomerleau, 1994; Pomerleau, Garcia, Pomerleau, & Cameron, 
1992; Steinberg & Cherek, 1989), the weight of  evidence for the most part favors 
the absence of phase differences in substance use. 
An exception to this generalization is provided by a number of studies docu- 
menting menstrual phase differences in the intake of alcohol (Belfer, Shader, 
Carroll, & Hermatz, 1971; Podolsky, 1963) and marijuana (Mello, 1986) in wom- 
en with premenstrual dysphoria. Intake peaked during the premenstruum, 
leading Mello (1986) to suggest that the depression and anxiety associated with 
the premenstruum in these women provoked episodic increases in drug use. In 
an effort to determine whether smoking also varies as a function of menstrual 
phase in female smokers with premenstrual symptomatology, whether other 
drug use also showed phase differences in these smokers, and whether increased 
substance use was associated with either affective disturbances or physical dis- 
comfort, we examined data from nine female smokers meeting criteria for Late 
Luteal Phase Dysphoric Disorder (LLPDD) who were asked to keep daily diaries 
rating menstrual symptomatology, smoking, and other substance intake. 
METHOD 
Subjects 
Subjects were nine female smokers who participated in a larger study de- 
signed to determine what percentage of women perceiving themselves as having 
premenstrual syndrome actually meet criteria for LLPDD as proposed in the 
D S M - I I I - R  (American Psychiatric Association, 1987) and whether those who 
met criteria had different family histories of psychopathology than those who 
did not (Marks, 1993; Marks, Hair, Klock, & Ginsburg, under  review). Subjects 
were recruited from the local community using advertisements in a local news- 
paper and a hospital employee newsletter seeking women who perceived them- 
selves as suffering from premenstrual syndrome to participate in a study of 
phase-related mood change. They were selected without regard to smoking sta- 
tus or smoking history. To be eligible, candidates were required: (a) to be be- 
tween the ages of 18 and 45; (b) to be in good health; (c) to not be taking any 
psychoactive medication or hormones, including oral contraceptives, currently 
or in the past 3 months; (d) to not be pregnant currently or within the past 6 
months, or planning a pregnancy during the course of the study; and (e) to have 
regular menstrual cycles. 
Following telephone screening, 75 women appeared to be eligible for the study 
and were scheduled for an initial interview. Twenty women canceled their appoint- 
ments, 5 were disqualified for failure to meet study criteria, and 25 withdrew after 
enrollment. Of  the 25 women who completed the study, 19 (9 smokers, 3 ex-smokers, 
7 lifetime nonsmokers) met criteria for LLPDD; the 9 smokers served as subjects 
in the present study. Subjects were paid for their participation in the study. 
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Subjects had a mean age of  31.8 (SD + 5.3) years and reported smoking a 
mean of  18.8 (SD + 4.9) cigarettes per day. All but two subjects (one with a 
history of  depression, one with a current diagnosis of social phobia and a history 
of  simple phobia and panic disorder) were free of  comorbid diagnoses. All but 
one subject were high school graduates, and six of  the nine had at least some 
college education. All subjects were employed--one  in an unskilled job, one in a 
semiskilled job, with the remainder professionally employed. Three subjects 
were married, three were divorced, and three were single; two had one or more 
children. All subjects were white. 
Procedure 
At the initial interview, the study was explained, informed consent obtained, 
and premenstrual symptomatology reviewed. The subject then completed the 
Premenstrual Assessment Form (Halbreich, Endicott, Schacht, & Nee, 1982), a 
retrospective self-report questionnaire containing 95 items querying premen- 
strual changes and collecting information about demographics, health, and 
menstrual cycle phenomena. 
The study required subjects to complete the 21-item Daily Ratings Form 
(DRF; Endicott & Halbreich, 1982; Endicott, Nee, Cohen, & Halbreich, 1986) 
for at least two consecutive menstrual cycles. The DRF prospectively assesses 
symptoms along five dimensions (dysphoric mood, physical discomfort, low en- 
ergy, more alcohol/sex/activity, and consumption). Substance intake is assessed 
by items querying smoking, intake of  alcohol and nonprescribed drugs (com- 
bined in a single item), and intake of  caffeinated beverages. In this study, three 
items (difficulty concentrating, decreased appetite, insomnia) were added to fa- 
cilitate diagnosis of  LLPDD. All 24 items were rated on a 6-point scale ranging 
from "not at all" to "extreme." Subjects were instructed to fill out the DRF at 
bedtime. Forms were mailed to the experimenter following each cycle using pre- 
addressed, postage-paid envelopes. 
Subjects were diagnosed as having LLPDD if their DRF ratings met at least 
one of  two sets of  criteria: (a) The method of  Rivera-Tovar and Frank (1990) 
requires a 30% increase above baseline during the 7 days prior to menses, com- 
pared with the 7 days after onset of  menses, for at least 5 of  the 10 symptoms 
listed in the Criterion B of  the D S M - I I I - R  criteria, over at least two menstrual 
cycles; average daily postmenstrual rating for these symptoms must be <3; (b) 
The "absolute severity criteria" of  Eckerd, Hurt, and Severino (1989; Hurt  et al., 
1992) require that 5 of  the 10 D S M - I I I - R  symptoms have at least one "severe" 
(--5) rating during the 6 days prior to menses and that ratings for at least 4 of  6 
days after menses be not greater than "minimal" (<--2), for at least half of  the 
recorded cycles. Both sets of  guidelines require that symptoms meeting criteria 
must include one of  the following: affective lability (mood swings), anger/ 
irritability, anxiety, or depressed mood. Data were collected for at least two com- 
plete cycles in all subjects. 
After submitting her last DRF, each subject attended a final session in which 
history of  psychopathology was assessed using a self-administered, computer- 
interactive version of  the National Institute of  Mental Health Diagnostic Inter- 
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view Schedule-III-R (C-DIS; Blouin, 1991). Both the initial and final interviews 
were conducted 1 to 7 days post menses. 
Analys i s  o f  Menstrual  Cycle  Data 
The statistical and conceptual problems involved in analyzing menstrual cycle 
data are widely recognized (Steege, 1989); even the most sophisticated meth- 
odologies have shortcomings. Our approach, based on the Society for Menstrual 
Cycle Research guidelines (Sommer, 1986), involved calculating means for five 
phases defined as follows: menses (all bleeding days), premenstrual ( -7  through - 1 
days before the onset of  bleeding), ovulatory ( -  16 through - 12 days before onset 
of  bleeding), postovulatory (-11 through - 8  days before the onset of bleeding), 
and postmenses (the end of menses to the beginning of the ovulatory phase), l 
Means were then compared using repeated-measures analyses of variance (AN- 
OVAs); a posteriori analyses were conducted using the Newman-Keuls test 
(Duncan, 1957; Winer, 1971). Although a few subjects provided data for three 
cycles, only data from the first two cycles were included to ensure comparability 
between cycles; because preliminary analyses produced no cycle or cycle-by- 
phase effects for any variable, data were pooled across cycles. 
Because our hypotheses related primarily to phasic changes in mood or physi- 
cal state, and because two of the dependent  variables (alcohol and nonprescribed 
drugs; caffeine) were embedded in the more alcohol/sex/activity and consump- 
tion dimensions, we restricted our analyses of menstrual symptomatology to the 
dysphoric mood and physical discomfort dimensions. The dysphoric mood di- 
mension included the following items: mood swings; irritable, angry, impatient; 
depressed, sad, low, blue, lonely; anxious, jittery, nervous; and stay home, avoid 
social activity. Items comprising the physical discomfort dimension were abdomi- 
nal pain; breast pain; less sexual interest; back, joint, or muscle pain; and feel 
bloated, have edema. Phase means for the DRF items querying smoking, intake 
of  alcohol and nonprescribed drugs, and intake of caffeinated beverages were 
also analyzed. Pearson intrasubject correlations were calculated for each subject 
to determine the association between each day's smoking and symptom ratings, 
independent  of phase. 
RESULTS 
Not surprisingly (because some of the symptoms contributing to this score 
formed the basis of  diagnosis), significant phase effects were detected for the 
dysphoric mood dimension (Figure 1, top panel; F(4, 32) = 6.31, p < .001), with 
self-ratings being high during menses, lowest during postmenses, then rising to a 
peak during the premenstrual phase. Post hoc analyses showed that premen- 
strual ratings significantly exceeded ratings for menses (p < .05), postmenses (p 
< .01), and the ovulatory phase (p < .01) and marginally exceeded the post- 
I These terms are preferred to follicular and luteal, which the guidelines suggest be reserved for 
phase designations based on direct biological measures. 

































































Top panel: Dally self-rating of  DRF Dysphoric  Mood Dimens ion  (mean for 
each phase col lapsed across two cycles;  score represents a mean of  f ive i tems scored on 
a scale o f  1 (not at all) to 6 (extreme).  Bottom panel: Daily self-rating of  DRF Physical  
Discomfort  D imens ion  (mean for each phase col lapsed across two cycles;  score repre- 
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Figure 2. Top panel: Daily self-rating of  DRF "Smoke" item (mean for each phase 
collapsed across two cycles); items are scored on a scale of  1 (not at all) to 6 (extreme). 
Center panel: Daily self-rating of  DRF "Drink alcohol/use nonprescribed drugs" item 
(mean for each phase collapsed across two cycles). Bottom panel: Daily self-rating of  
DRF "Drink coffee" item (mean for each phase collapsed across two cycles) (Mean - 
SEM; N = 9). 
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ovulatory phase (p < .  10). Postovulatory phase ratings marginally exceeded rat- 
ings for the ovulatory phase (p < .10). Significant phase effects were likewise 
observed for the physical discomfort dimension (bottom panel; F(4, 32) = 12.49, 
p < .001), with ratings reflecting a pattern similar to that for the dysphoric mood 
dimension. Premenstrual ratings significantly exceeded those for postmenses (p 
< .01), the ovulatory phase (p < .01), and the postovulatory phase (p < .05). 
Ratings for the menstrual phase were significantly higher than for the post- 
menses (p < .01) and the ovulatory phase (p < .01). Postovulatory ratings signifi- 
cantly exceeded ratings for the postmenstrual (p < .05) and ovulatory (p < .05) 
phases. 
As shown in Figure 2 (top panel), ratings of amount of smoking varied signifi- 
cantly across menstrual phase (F(4, 32) = 3.41, p < .05), with peak intake occur- 
ring during the menses. Menstrual phase ratings significantly exceeded 
postovulatory ratings (p < .01) and marginally exceeded ratings for both the 
postmenstrual (p < .  10) and premenstrual phases (p < .  10). Ratings of intake of 
alcohol and nonprescribed drugs also varied significantly across menstrual phase 
(center panel; F(4, 32) = 3.84, p < .05), again peaking during the menses. Rat- 
ings during menses significantly exceeded those during all other phases (post- 
menses, p < .05; ovulatory, p < .01; postovulatory, p < .05; and premenstruum, p 
< .05). Ratings of  caffeine intake (bottom panel), by contrast, did not vary across 
phase (F(4, 32) = 0.23, n.s.). 
For the dysphoric mood dimension, mean intrasubject correlations with 
smoking were r = +.17 during the first month and r = +.19 for the second 
month; corresponding means for the physical discomfort dimension were r -- 
+.06 and r = +.05. No more than three subjects showed a significant correlation 
for either scale for either month. 
D I S C U S S I O N  
Significant menstrual phase effects were observed for both physical and affec- 
tive symptomatology, with both peaking in the premenstruum (though mean 
levels were not remarkably high for any phase). Subjects also showed significant 
menstrual phase differences in smoking. Although there was some suggestion of 
the predicted increase during the premenstruum, the only significant elevation 
occurred during the menses. A similar pattern emerged for alcohol and non- 
prescribed drugs, with the association of  increased consumption with the menses 
being even more pronounced. 
The failure of  peak smoking ratings to correspond with peak symptomatol- 
ogy, combined with the unimpressive mean intrasubject correlations of  symp- 
tomatology with smoking, suggests that the explanation for phase differences in 
smoking lies elsewhere (e.g., a phase lag in response, or a greater tendency of  
women with LLPDD to increase smoking in response to dysmenorrhea) than in 
the symptoms examined. 
The  lumping of  alcohol with unspecified nonprescription drugs in the DRF 
complicates interpretation of this variable. Because cigarette smoking often 
accompanies marijuana as well as alcohol use (Mello, Mendelson, Sellers, & 
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Kuehnle, 1980), it is possible that changes in smoking influenced use of either or 
both drugs (or vice versa). Likewise, it is impossible to dismiss the possibility that 
a similar pattern for this variable reflects an increase in use of over-the-counter 
painkillers during menses. Thus, our study cannot be interpreted as a disconfir- 
mation of previous findings of peak intake of alcohol and marijuana during the 
premenstruum in women with premenstrual dysphoria (Belfer et al., 1971; 
Mello, 1986; Podolsky, 1963). Failure to detect phase-related changes in caffeine 
consumption suggests that even if the underlying mechanisms for phase effects 
on substance intake in women with LLPDD cut across drugs, they do not neces- 
sarily extend to all drugs. 
Several additional methodological limitations must be mentioned. The use of 
ratings collected once at the end of the day, using a relational Likert-type scale 
rather than quantitative data, constitutes a highly imprecise reflection of smok- 
ing rate and drug intake. Because of these limitations, the actual magnitude of 
the differences in intake cannot be determined and may be quite small in clinical 
terms. It must also he noted that subjects were not blind to our interest in the 
menstrual cycle and may have been influenced by expectancies; given the focus 
on LLPDD, however, such expectancies should have been reflected by maximum 
ratings during the premenstrual phase, when in fact the highest ratings were 
observed during menses. Finally, because diaries were collected only at the end 
of each cycle, we cannot be sure that subjects actually completed them on a daily 
basis, undermining the prospective nature of the study. 
Because of growing evidence of a connection between smoking and a number 
of psychopathological conditions, including depression (Glassman, 1993; Glass- 
man et al., 1990; Kendler et al., 1993), alcoholism (Dreher & Fraser, 1967; Istvan 
& Matarazzo, 1984), and eating disorders (Pomerleau & Krahn, 1993), many 
clinical researchers believe that success in treating smoking in individuals with 
these conditions will be greatly enhanced by the development of properly timed 
pharmacological or behavioral interventions that address these co-factors as well. 
I f  our findings can be replicated in a larger number of subjects, using more 
precise measures of nicotine intake, they may likewise help us to recognize and 
address the special needs of smokers with LLPDD. 
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